MARKET

OKYO

OKYO

OKYO PHARMA LTD
NASDAQ
1.450
-0.030
-2.03%
After Hours: 1.420 -0.03 -2.07% 17:15 05/09 EDT
OPEN
1.450
PREV CLOSE
1.480
HIGH
1.507
LOW
1.420
VOLUME
5.80K
TURNOVER
--
52 WEEK HIGH
1.740
52 WEEK LOW
0.8075
MARKET CAP
49.06M
P/E (TTM)
-0.0442
1D
5D
1M
3M
1Y
5Y
1D
HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
Benzinga · 4d ago
Weekly Report: what happened at OKYO last week (0428-0502)?
Weekly Report · 4d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: OKYO Pharma Limited Sponsored ADR (OKYO), Biogen (BIIB) and Cigna (CI)
TipRanks · 4d ago
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain
TipRanks · 05/01 11:32
Okyo Pharma announces FDA granted FTD to urcosimod
TipRanks · 05/01 11:20
Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target
TipRanks · 04/30 14:25
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain
TipRanks · 04/30 11:31
Okyo Pharma announces plans to accelerate development of urcosimod
TipRanks · 04/30 11:15
More
About OKYO
More
OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
Recently
Symbol
Price
%Change

Webull offers OKYO Pharma Ltd stock information, including NASDAQ: OKYO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OKYO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OKYO stock methods without spending real money on the virtual paper trading platform.